The Regenerative Power of Erythropoietin in Plastic and Reconstructive Surgery.

Several human studies show positive signals, while research methods and sample sizes continue to develop.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Erythropoietin (EPO) is a glycoprotein hormone stimulating erythropoiesis. Over the last two decades, EPO has additionally gained attention as a therapeutic compound in plastic and reconstructive surgery. This is mainly due to its pleiotropic action profile, which promotes angiogenesis, suppresses apoptosis, and modulates inflammation, resulting in enhanced tissue regeneration. Accordingly, many studies have demonstrated the efficacy of EPO and its derivatives in the management of wound healing, flap surgery, peripheral nerve regeneration, fat grafting, and bone repair. However, for the broad clinical implementation of EPO as a therapeutic in these fields, several critical steps are yet to be taken. These include the development of standardized and safe treatment protocols and their evaluation in randomized multicenter clinical trials for the establishment of personalized, targeted therapies adapted to the specific needs of surgical patients. If this succeeds, EPO treatment may markedly improve the outcome of many different therapeutic approaches in regenerative medicine and reconstructive surgery.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.